Neurosteer

Neurosteer operates at the intersection of medical devices, digital health, neuroscience, and clinical research. Its differentiation is technical and workflow-oriented: the company combines a wearable single-channel medical-grade EEG with cloud processing, real-time brain-activity metrics, and a browser-based management portal. The platform is designed to support both detection and longitudinal monitoring across Parkinson’s disease, Alzheimer’s disease, dementia, epilepsy, cognitive decline, mood conditions, and neurofeedback applications. That breadth gives Neurosteer a wider use-case scope than a narrowly focused diagnostic device, while its FDA-cleared platform provides a stronger regulatory signal than an unregulated consumer wellness wearable. The company also emphasizes objective biomarkers and signal decomposition from a single EEG channel, potentially reducing equipment and setup complexity relative to multi-channel systems. Its current market position is therefore best described as an early-stage, specialized neurotechnology provider with healthcare and research applicability. The main commercial questions are clinical adoption, reimbursement, evidence quality across indications, and the extent to which its compact form factor translates into repeatable outcomes outside controlled studies.

Neurosteer’s trajectory shows a long product-development cycle followed by regulatory and application expansion. Founded in 2015, it raised $2.0 million in Seed funding that September, received an $82,941 grant in 2018, and raised a further $4.5 million Seed round on Jun 1, 2019, bringing total funding to $6,582,941. The 2019 round is the latest recorded financing, suggesting that growth has not been accompanied by a recently disclosed institutional funding step-up. Product development has nevertheless progressed from the hdrEEG™ forehead sensor and cloud signal-processing architecture to a broader platform comprising assessment, monitoring, neurofeedback, and portal software. FDA clearance announced on Nov 3, 2022 marked the clearest inflection point, moving the company beyond research-only positioning toward regulated clinical use. Patent activity in 2022 and 2024 indicates continued investment in brain-activity interpretation and stimulation-related applications. The 2025 Huemn deployment demonstrates an additional commercial use case in brain-health services. Overall, the trajectory reflects technical maturation and market experimentation, with limited visibility into scale, revenue, or financing after 2019.